CSL Ltd Annual Report 2021

Immunology Clinical Registration Post-Launch HAEGARDA ® (C1 Esterase Inhibitor subcutaneous) Hereditary Angioedema HIZENTRA ® (20% subcutaneous Ig) Multiple Indications PRIVIGEN ® (10% intravenous Ig) Multiple Indications Garadacimab (Anti-FXIIa mAb) Hereditary Angioedema HIZENTRA ® (20% subcutaneous Ig) Dermatomyositis HIZENTRA ® (20% subcutaneous Ig) Systemic Sclerosis CSL324 (Anti-G-CSFRmAb) Hidradenitis Suppurativa CSL730 (Recombinant Trivalent Human IgG1 Fc Multimer) Multiple Indications* Haematology Clinical Registration Post-Launch AFSTYLA ® (Recombinant FVIII) Haemophilia A IDELVION ® (Recombinant rFIX-FP) Haemophilia B EtranaDez (Etranacogene dezaparvovec; formerly AMT-061) Haemophilia B KCENTRA ® (Prothrombin Complex Concentrate) Trauma CSL889 (Hemopexin) Sickle Cell Disease Respiratory Clinical Registration Post-Launch ZEMAIRA ® /RESPREEZA ® (Alpha-1 Proteinase Inhibitor) A1-PI Deficiency Garadacimab (Anti-FXIIa mAb) Interstitial Lung Disease CSL311 (Anti-Beta Common mAb) Asthma CSL787 (Nebulised Ig) Non-Cystic Fibrosis Bronchiectasis Cardiovascular and Metabolic Clinical Registration Post-Launch CSL112 [Apolipoprotein A-I (human)] Acute Coronary Syndrome CSL346 (Anti-VEGF-BmAb) Diabetic Kidney Disease Transplant Clinical Registration Post-Launch Clazakizumab (Anti-IL-6mAb) Chronic Active Antibody-Mediated Rejection CSL964 (Alpha-1 Antitrypsin) Prevention of Graft-versus-Host Disease CSL964 (Alpha-1 Antitrypsin) Treatment of Graft-versus-Host Disease* Influenza Vaccines Clinical Registration Post-Launch AUDENZ™ [Adjuvanted cell-based influenza A (H5N1) pandemic vaccine] AFLURIA ® Quadrivalent (Egg-based Influenza Vaccine) FLUAD ® Trivalent (Adjuvanted Influenza Vaccine) FLUAD ® Quadrivalent (Adjuvanted Influenza Vaccine) FLUCELVAX ® Quadrivalent (Cell-based Influenza Vaccine) FOCLIVIA ® /FOCETRIA [Adjuvanted egg-based influenza A (H5N1) pandemic vaccine] PANVAX ® [Alum-adjuvanted egg-based influenza A (H5N1) pandemic vaccine] Adjuvanted Cell Culture Influenza Vaccine (aQIVc) Outlicensed Programs Clinical Registration Post-Launch ASLAN004 (Anti-IL-13RmAb) Atopic Dermatitis Mavrilimumab (Anti-GM-CSFRmAb) Giant Cell Arteritis, COVID-19 * Partnered projects. CSL’s pipeline also includes Life Cycle Management projects that address regulatory post-marketing commitments, pathogen safety, capacity expansions, yield improvements, and new packages and sizes. Global Research and Development Pipeline 2020/21 CSL Limited Annual Report 2020/21 12